|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Association of Fusobacterium nucleatum with immunity andmolecular alterations in colorectal cancer显示文摘The human intestinal microbiome plays a major role in human health and diseases, including colorectal cancer. Colorectal carcinogenesis represents a heterogeneous process with a differing set of somatic molecular alterations, influenced by diet, environmental and microbial exposures, and host immunity. Fusobacterium species are part of the human oral and intestinal microbiota. Metagenomic analyses have shown an enrichment of Fusobacterium nucleatum(F. nucleatum) in colorectal carcinoma tissue. Using 511 colorectal carcinomas from Japanese patients, we assessed the presence of F. nucleatum. Our results showed that the frequency of F. nucleatum positivity in the Japanese colorectal cancer was 8.6%(44/511), which was lower than that in United States cohort studies(13%). Similar to the United States studies, F. nucleatum positivityin Japanese colorectal cancers was significantly associated with microsatellite instability(MSI)-high status. Regarding the immune response in colorectal cancer, high levels of infiltrating T-cell subsets(i.e., CD3+, CD8+, CD45RO+, and FOXP3+ cells) have been associated with better patient prognosis. There is also evidence to indicate that molecular features of colorectal cancer, especially MSI, influence T-cell-mediated adaptive immunity. Concerning the association between the gut microbiome and immunity, F. nucleatum has been shown to expand myeloid-derived immune cells, which inhibit T-cell proliferation and induce T-cell apoptosis in colorectal cancer. This finding indicates that F. nucleatum possesses immunosuppressive activities by inhibiting human T-cell responses. Certain micro RNAs are induced during the macrophage inflammatory response and have the ability to regulate host-cell responses to pathogens. Micro RNA-21 increases the levels of IL-10 and prostaglandin E2, which suppress antitumor T-cell-mediated adaptive immunity through the inhibition of the antigen-presenting capacities of dendritic cells and T-cell proliferation in colorectal cancer cells. Thus, emerging evidence may provide insights for strategies to target microbiota, immune cells and tumor molecular alterations for colorectal cancer prevention and treatment. Further investigation is needed to clarify the association of Fusobacterium with T-cells and micro RNA expressions in colorectal cancer. | Katsuhiko Nosho Yasutaka Sukawa Yasushi Adachi Miki Ito Kei Mitsuhashi Hiroyoshi Kurihara Shinichi Kanno Itaru Yamamoto Keisuke Ishigami Hisayoshi Igarashi Reo Maruyama Kohzoh Imai Hiroyuki Yamamoto Yasuhisa Shinomura | 2016 | World Journal of Gastroenterology2016，22，2： | 44 |
| 2 | HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer显示文摘BACKGROUND The clinical significance of intratumoral human epidermal growth factor receptor 2(HER2)heterogeneity is unclear for HER2-positive gastric cancer,although it has been reported to be a significant prognosticator for HER2-positive breast cancer,which has received trastuzumab-based chemotherapy.AIM To clarify the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer,which has received trastuzumab-based chemotherapy.METHODS Patients with HER2-positive unresectable or metastatic gastric cancer who received trastuzumab-based chemotherapy as a first line treatment were included.The patients were classified into two groups according to their intratumoral HER2 heterogeneity status examined by immunohistochemistry(IHC)on endoscopic biopsy specimens before treatment,and their clinical response to chemotherapy and survival were compared.RESULTS A total of 88 patients were included in this study,and HER2 heterogeneity was observed in 23(26%)patients(Hetero group).The overall response rate was significantly better in patients without HER2 heterogeneity(Homo group)(Homo vs Hetero:79.5%vs 35.7%,P=0.002).Progression-free survival of trastuzumab-based chemotherapy was significantly better in the Homo group(median,7.9 vs 2.5 mo,HR:1.905,95%CI:1.109-3.268).Overall survival was also significantly better in the Homo group(median survival time,25.7 vs 12.5 mo,HR:2.430,95%CI:1.389-4.273).Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors(HR:3.115,95%CI:1.610-6.024).CONCLUSION IHC of HER2 heterogeneity is the pivotal predictor for trastuzumab-based chemotherapy.Thus,HER2 heterogeneity should be considered during the assessment of HER2 expression. | Akio Kaito Takeshi Kuwata Masanori Tokunaga Kohei Shitara Reo Sato Tetsuo Akimoto Takahiro Kinoshita | 2019 | World Journal of Clinical Cases2019，7，15： | 5 |
| 3 | Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes显示文摘The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 inhibitor, showing that the DPP-4 inhibitors may be an effective and safe oral anti-diabetic drug for steroid-induced diabetes. | Hidekatsu Yanai Yoshinori Masui Reo Yoshikawa Junwa Kunimatsu Hiroshi Kaneko | 2010 | World Journal of Diabetes2010，1，3： | 4 |
| 4 | Intravenous immune globulin suppresses angiogenesis in mice and humans显示文摘Human intravenous immune globulin(IVIg),a purified IgG fraction composed of~60%IgG1 and obtained from the pooled plasma of thousands of donors,is clinically used for a wide range of diseases.The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG(IgG)Fc regions.Recently,we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI,a high-affinity receptor for IgG1.Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases,namely,neovascular age-related macular degeneration,corneal neovascularization,colorectal cancer,fibrosarcoma and peripheral arterial ischemic disease.Angioinhibition was mediated by the Fc region of IVIg,required FcγRI and had similar potency in transgenic mice expressing human FcγRs.Finally,IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities.These data place IVIg,an agent approved by the US Food and Drug Administration,as a novel angioinhibitory drug in doses that are currently administered in the clinical setting.In addition,they raise the possibility of an unintended effect of IVIg on blood vessels. | Reo Yasuma Valeria Cicatiello Takeshi Mizutani Laura Tudisco Younghee Kim Valeria Tarallo Sasha Bogdanovich Yoshio Hirano Nagaraj Kerur Shengjian Li Tetsuhiro Yasuma Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Balamurali K Ambati Sevim Barbasso Helmers Ingrid E Lundberg Ondrej Viklicky Jeanette HW Leusen J Sjef Verbeek Bradley D Gelfand Ana Bastos-Carvalho Sandro De Falco Jayakrishna Ambati | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 3 |
| 5 | Kinetic analyses of liver phosphatidylcholine and phosphatidylethanolamine biosynthesis using13C NMR spectroscopy 显示文摘 | REO N V ADINEHZADEH M FOY B D | 2002 | Biochim Biophys Acta2002，1580，： | 1 |
| 6 | Evaluation of a taste sensor instrument(electronic tongue) for use in formulation development显示文摘 | Lorenz J.K Reo J.P Hendl O | | 0，，1： | 1 |
| 7 | NMR-based metabolomics显示文摘 | Reo NV | 2002 | Drug Chem Toxicol2002，25，： | 1 |
| 8 | NMR-based metabolomics显示文摘 | Reo N V | 2002 | Drug Chem Toxicol2002，25，4： | 1 |
| 9 | NMR-based metabolomics显示文摘 | Reo NV | 2002 | Drug Chem Toxicol2002，25，4： | 1 |
| 10 | Evaluation of a taste sensor instrument (electronic tongue) for use in formulation development显示文摘 | Lorenz Julie K Reo Joseph P Hendl Ondrej | 2009 | Int J Pharm2009，367，12： | 1 |
| 11 | systems 显示文摘 | HUMENBERGER M ZINNER C WEBER M : A fast ste for embedded real- reo matching algorithm suitable sion and Image Under 1180-1202 | 2010 | Computer Vi- standing2010，，： | 1 |
| 12 | Computer model prediction of heating, soaking and cooling time in batch annealing 显示文摘 | Reo T K Barth G J | 1983 | Iron and Steel Engineer1983，60，9： | 1 |
| 13 | Atrazine sensor based on molecularly imprinted polymer-modified gold electrod 显示文摘 | REO S TOSHIFUMI T LZUMI K | 2003 | Anal Chem2003，75，18： | 1 |
| 14 | Atrazine sensor based on molecularly imprinted polymer-modified gold electrode显示文摘 | REO S TOSHIFUMI IZUMI K | 2003 | Anal Chem2003，75，： | 1 |
| 15 | Prevention of Falls in Older Patients显示文摘 | Reo S S | 2005 | Am Fam Physician2005，72，1： | 1 |
| 16 | Evaluation of a taste sensor instrument (electronic tongue) for use in formulation development 显示文摘 | Lorenz J K Reo J P Hendl O | 2009 | Int J Pharm2009，367，12： | 1 |
| 17 | Recovery and Reconstruction Calendar,Journal of Disaster Research显示文摘 | REO KIMURA | 2007 | 2(6):465-4742007，2，6： | 1 |
| 18 | NMR-based metabolomics 显示文摘 | Reo NV | 2002 | Drug Chem Toxicol2002，25，： | 1 |
| 19 | Atrazine sensor based on molecularly imprinted polymer-modified gold electrode显示文摘 | REO S TOSHIFUM I IZUMI K | 2003 | Anal Chem2003，75，： | 1 |
| 20 | NMR-BASED METABOLOMICS显示文摘 | Nicholas V. Reo | 2002 | Drug and Chemical Toxicology2002，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员